These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cytoplasmic, nuclear, and total PBK/TOPK expression is associated with prognosis in colorectal cancer patients: A retrospective analysis based on immunohistochemistry stain of tissue microarrays. Su TC; Chen CY; Tsai WC; Hsu HT; Yen HH; Sung WW; Chen CJ PLoS One; 2018; 13(10):e0204866. PubMed ID: 30286126 [TBL] [Abstract][Full Text] [Related]
3. PBK promotes aggressive phenotypes of cervical cancer through ERK/c-Myc signaling pathway. Ma H; Han F; Yan X; Qi G; Li Y; Li R; Yan S; Yuan C; Song K; Kong B J Cell Physiol; 2021 Apr; 236(4):2767-2781. PubMed ID: 33184870 [TBL] [Abstract][Full Text] [Related]
4. PBK Enhances Cellular Proliferation With Histone H3 Phosphorylation and Suppresses Migration and Invasion With CDH1 Stabilization in Colorectal Cancer. Koshino A; Nagano A; Ota A; Hyodo T; Ueki A; Komura M; Sugimura-Nagata A; Ebi M; Ogasawara N; Kasai K; Hosokawa Y; Kasugai K; Takahashi S; Inaguma S Front Pharmacol; 2021; 12():772926. PubMed ID: 35115926 [TBL] [Abstract][Full Text] [Related]
5. BZW2 promotes the malignant progression of colorectal cancer via activating the ERK/MAPK pathway. Huang L; Chen S; Fan H; Ai F; Sheng W J Cell Physiol; 2020 May; 235(5):4834-4842. PubMed ID: 31643092 [TBL] [Abstract][Full Text] [Related]
6. miR-216b promotes cell growth and enhances chemosensitivity of colorectal cancer by suppressing PDZ-binding kinase. Zou J; Kuang W; Hu J; Rao H Biochem Biophys Res Commun; 2017 Jun; 488(2):247-252. PubMed ID: 28373071 [TBL] [Abstract][Full Text] [Related]
8. PDZ-binding kinase inhibitor OTS514 suppresses the proliferation of oral squamous carcinoma cells. Kato M; Ota A; Ono T; Karnan S; Hyodo T; Rahman ML; Hasan MN; Onda M; Kondo S; Ito K; Furuhashi A; Hayashi T; Konishi H; Tsuzuki S; Hosokawa Y; Kazaoka Y Oral Dis; 2024 Mar; 30(2):223-234. PubMed ID: 36799330 [TBL] [Abstract][Full Text] [Related]
9. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis. Gao T; Hu Q; Hu X; Lei Q; Feng Z; Yu X; Peng C; Song X; He H; Xu Y; Zuo W; Zeng J; Liu Z; Yu L Cancer Lett; 2019 Mar; 445():11-23. PubMed ID: 30590102 [TBL] [Abstract][Full Text] [Related]
10. PBK Expression Is Associated With Prognosis of Patients With Oral Squamous Cell Carcinoma Treated With Radiotherapy: A Retrospective Study. Yu WN; Lin HF; Lee YI; Shia WC; Sung WW; Yeh CM; Lin YM Anticancer Res; 2021 Apr; 41(4):2177-2182. PubMed ID: 33813430 [TBL] [Abstract][Full Text] [Related]
11. Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase. Diao X; Yang D; Chen Y; Liu W Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898980 [TBL] [Abstract][Full Text] [Related]
12. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Stefka AT; Johnson D; Rosebeck S; Park JH; Nakamura Y; Jakubowiak AJ Cancer Med; 2020 Jan; 9(1):324-334. PubMed ID: 31714026 [TBL] [Abstract][Full Text] [Related]
13. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase. Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S; Mu X Anticancer Agents Med Chem; 2019; 19(8):1029-1036. PubMed ID: 30827262 [TBL] [Abstract][Full Text] [Related]
15. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC. Kar A; Zhang Y; Yacob BW; Saeed J; Tompkins KD; Bagby SM; Pitts TM; Somerset H; Leong S; Wierman ME; Kiseljak-Vassiliades K Endocr Relat Cancer; 2019 Oct; 26(10):765-778. PubMed ID: 31325906 [TBL] [Abstract][Full Text] [Related]
16. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo. Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429 [TBL] [Abstract][Full Text] [Related]
17. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy. Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332 [TBL] [Abstract][Full Text] [Related]
18. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma. Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048 [TBL] [Abstract][Full Text] [Related]
19. Relationships among Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081 [TBL] [Abstract][Full Text] [Related]
20. PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis and cell proliferation and viability in lung adenocarcinoma. Lei B; Qi W; Zhao Y; Li Y; Liu S; Xu X; Zhi C; Wan L; Shen H Hum Pathol; 2015 Feb; 46(2):217-24. PubMed ID: 25466965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]